Radiology, Vol 194, 795-800, Copyright © 1995 by Radiological Society of North America

ARTICLES

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

DJ Yang, S Wallace, A Cherif, C Li, MB Gretzer, EE Kim and DA Podoloff
Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston 77030.

PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET). MATERIALS AND METHODS: Biodistribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined. RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 +/- 0.599, 2.41 +/- 0.567 and 8.02 +/- 2.420, respectively, and tumor-to-muscle ratios of 0.66 +/- 0.267, 2.11 +/- 0.347, and 5.92 +/- 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor. CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.

This article has been cited by other articles:

				J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies Mol. Cancer Ther., December 1, 2006; 5(12): 2991 - 3000. [Abstract] [Full Text] [PDF]

				H. Yuan, T. Schroeder, J. E. Bowsher, L. W. Hedlund, T. Wong, and M. W. Dewhirst Intertumoral Differences in Hypoxia Selectivity of the PET Imaging Agent 64Cu(II)-Diacetyl-Bis(N4-Methylthiosemicarbazone) J. Nucl. Med., June 1, 2006; 47(6): 989 - 998. [Abstract] [Full Text] [PDF]

				S.-M. Eschmann, F. Paulsen, M. Reimold, H. Dittmann, S. Welz, G. Reischl, H.-J. Machulla, and R. Bares Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy J. Nucl. Med., February 1, 2005; 46(2): 253 - 260. [Abstract] [Full Text] [PDF]

				S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]

				T. Tolvanen, K. Lehtio, J. Kulmala, V. Oikonen, O. Eskola, J. Bergman, and H. Minn 18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies J. Nucl. Med., December 1, 2002; 43(12): 1674 - 1680. [Abstract] [Full Text] [PDF]

				E. L. Engelhardt, R. F. Schneider, S. H. Seeholzer, C. C. Stobbe, and J. D. Chapman The Synthesis and Radiolabeling of 2-Nitroimidazole Derivatives of Cyclam and Their Preclinical Evaluation as Positive Markers of Tumor Hypoxia J. Nucl. Med., June 1, 2002; 43(6): 837 - 850. [Abstract] [Full Text] [PDF]

				K. Lehtio, V. Oikonen, T. Gronroos, O. Eskola, K. Kalliokoski, J. Bergman, O. Solin, R. Grenman, P. Nuutila, and H. Minn Imaging of Blood Flow and Hypoxia in Head and Neck Cancer: Initial Evaluation with [15O]H2O and [18F]Fluoroerythronitroimidazole PET J. Nucl. Med., November 1, 2001; 42(11): 1643 - 1652. [Abstract] [Full Text] [PDF]

				T. Gronroos, O. Eskola, K. Lehtio, H. Minn, P. Marjamaki, J. Bergman, M. Haaparanta, S. Forsback, and O. Solin Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET J. Nucl. Med., September 1, 2001; 42(9): 1397 - 1404. [Abstract] [Full Text] [PDF]